Alessandro Isidori, MD, PhD, Marche Nord Hospital, Pesaro, Italy, discusses current immunotherapeutic agents under investigation for the treatment of acute myeloid leukemia (AML), drawing focus on sabatolimab and magrolimab. Dr Isidori first explains the mechanism of action of sabatolimab, and highlights promising clinical trial data that has been observed with the use of this agent. Following this, Dr Isidori discusses the promising role of magrolimab in patients with TP53-mutated disease, and ongoing trials in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.